10-Q: BioRegenx Reports Q1 2025 Results: Sales Dip, Losses Narrow Amid Cost-Cutting Efforts

BioRegenx's Q1 2025 results show a decrease in net sales but a significant reduction in net loss due to decreased operating expenses.

Summary

• BioRegenx, Inc. reported its financial results for the first quarter of 2025.
• Net sales decreased by 6% to $515,147 compared to $549,548 in Q1 2024, attributed to product issues with the medical testing machine affecting nutritional sales.
• Cost of sales decreased by 34% to $109,116, resulting in a gross profit of $406,031.
• Operating expenses significantly decreased by 83% to $598,646, primarily due to a reduction in equity compensation.
• The company's net loss decreased by 92% to $266,854 from $3,152,458 in the same period last year.
• The company had cash and cash equivalents of $83,625 as of March 31, 2025.
• The company's notes payable of $522,500 are in default.
• The company is pursuing additional debt or equity financing to fund ongoing operations and working capital.
• The company has identified material weaknesses in its internal control over financial reporting.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company significantly reduced its net loss, it also experienced a decrease in sales and faces significant financial challenges, including notes in default and material weaknesses in internal controls. The need for additional financing adds uncertainty.

Positives

• Net loss significantly decreased by 92% to $266,854 in Q1 2025 from $3,152,458 in Q1 2024.
• Operating expenses decreased by 83% due to lower equity compensation.
• Cost of sales decreased by 34% for the three months ended March 31, 2025 compared to the three months ended March 31, 2024.

Negatives

• Net sales decreased by 6% to $515,147 in Q1 2025 compared to $549,548 in Q1 2024.
• The company's notes payable of $522,500 are in default.
• The company identified material weaknesses in internal controls.
• As of March 31, 2025, the Company was delinquent on payments on two of the EIDL loans in the aggregate amount of $400,000.

Risks

• The company's ability to continue as a going concern is dependent on obtaining debt or equity financing.
• The company has notes payable of $522,500 in default.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company is involved in legal proceedings, including a lawsuit from GlycoCheck B.V. claiming damages in excess of $566,682.
• The company is delinquent on payments on two of the EIDL loans in the aggregate amount of $400,000.

Future Outlook

Management intends to raise additional debt or equity financing to fund ongoing operations and for necessary working capital; however, there is no assurance that such financing plans will be successful or be obtained in amounts sufficient to meet the Company's needs.

Industry Context

The company operates in the medical test equipment, nutritional products, and wellness devices industries, which are subject to regulatory oversight and competition from other companies offering similar products and services.

Comparison to Industry Standards

• It is difficult to compare BioRegenx's results directly to industry standards without knowing the specific sub-segments it operates in and the size of comparable companies.
• Given the company's size and financial challenges, it is likely underperforming compared to larger, more established players in the medical device and nutritional supplement markets.
• Companies like Abbott, Medtronic, and Nestle have significantly more resources and established distribution channels.

Legal Proceedings

• GlycoCheck B.V. filed a complaint against the Company and its subsidiary, MicroVascular Health Solutions, LLC, alleging breach of contract and related damages resulting from unpaid royalties and unjust enrichment, claiming damages in excess of $566,682.

Related Party Transactions

• The Company rents its home office from BBD Holdings, LLC which is controlled by Joseph Bird, an officer and director.
• Certain related party loans are secured by all assets of the Company or all assets of a subsidiary as evidenced by UCC Financing Statements.

Stakeholder Impact

• Shareholders face potential dilution from future equity financing.
• Employees face uncertainty due to the company's financial instability.
• Customers may be affected by product issues and potential disruptions in service.
• Creditors face risk due to the company's notes in default.

Next Steps

• The company intends to raise additional debt or equity financing.
• The company is negotiating terms of a revised royalty agreement with the VHS Pool Member.
• The company is obligated to exercise a purchase option to purchase the intangible property for $1,000,000, payable in common shares of the Company at a time of its choosing within the sub-license term.

Key Dates

Keywords

financial results, quarterly report, BioRegenx, net sales, net loss, operating expenses, medical test equipment, nutritional products, wellness devices, going concern, internal controls, EIDL loans, default, financing